Presented at PEGS Europe, November 2016, Lisbon, Portugal
Advances in Kymab’s Fully Integrated, B-Cell Repertoire Analysis and Hit Selection Capabilities
David Melvin, Ph.D., Director of Informatics, Kymab Limited
Kymab have developed an advanced technology to visualise and deeply explore the Kymouse™ antibody repertoire. We can identify candidate-quality molecules with exceptionally broad diversity and with the quality of fully human antibodies. Our platform allows rapid, detailed and efficient exploration of the B-cell response to immunisation as well as informing and supporting decision making process throughout our discovery program. We will present our work with the Bill and Melinda Gates foundation.